Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment

早期使用VIRTUGUIDE™的外科医生报告称，与传统治疗相比，手术时间减少了30分钟。

1

1

,2

，2

,

，

*

*

,

，

**

**

WEST CHESTER, Penn.

西切斯特，宾夕法尼亚州

,

，

July 29, 2025

2025年7月29日

/PRNewswire/ --

/PRNewswire/ --

Johnson & Johnson (NYSE: JNJ)

强生公司（纽约证券交易所代码：JNJ）

– Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the

－－强生医疗科技公司（Johnson & Johnson MedTech），作为全球骨科技术和解决方案的领导者，今天宣布推出

VIRTUGUIDE™ System

VIRTUGUIDE™ 系统

. This AI-powered, patient-matched solution is designed to support Lapidus procedures

这款由人工智能驱动、患者匹配的解决方案旨在支持Lapidus手术。

2

2

, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).

，一种通过连接足弓附近的两块骨头（第一跖骨和内侧楔骨）来帮助重新对齐足部的拇囊炎手术。

3

3

The system uses pre-operative planning software, developed in collaboration with PeekMed

该系统使用与PeekMed合作开发的术前规划软件。

®

®

, to assess each patient's bunion and make personalized recommendations for the intended correction.

，评估每位患者的拇囊炎情况，并为预期的矫正提供个性化建议。

2

2

Bunions are among the most common foot problems, affecting nearly one-third of adults in the U.S.

拇囊炎是最常见的足部问题之一，影响着美国近三分之一的成年人。

4

4

, yet traditional Lapidus surgery to treat the condition is often challenging.

，然而传统的Lapidus手术治疗这种情况通常具有挑战性。

5

5

,6

，6

The VIRTUGUIDE™ AI Lapidus System addresses this by enabling a streamlined approach and reducing surgical complexity.

VIRTUGUIDE™ AI Lapidus 系统通过简化手术流程和降低手术复杂性来解决这一问题。

2

2

** Early users estimated procedural time savings of at least 30 minutes when using the system compared to their previous technique.

早期用户估计，与之前的技术相比，使用该系统至少可以节省30分钟的程序时间。

1

1

,

，

*

*

'VIRTUGUIDE™ has completely transformed my approach to bunion surgery, making a complex Lapidus procedure significantly easier and faster. Since adopting VIRTUGUIDE™, my surgical corrections have been spot-on—what I plan preoperatively is exactly what I achieve in the operating room,' said Michael Campbell, M.D., FAAOS, a board-certified orthopaedic surgeon at Atlantic Orthopaedic Specialists..

“VIRTUGUIDE™完全改变了我对拇囊炎手术的方式，使得复杂的Lapidus手术变得显著更容易和快捷。自从采用VIRTUGUIDE™以来，我的手术矫正效果非常精准——我术前计划的内容与我在手术室中实现的结果完全一致，”大西洋骨科专家、董事会认证的骨科医生迈克尔·坎贝尔博士（Michael Campbell, M.D., FAAOS）表示。

±

±

'This improved accuracy leads to better outcomes, and the ability to present the pre-operative plan to my patients helps address their questions and ease their concerns

这种提高的精确性带来了更好的结果，而且能够向患者展示术前计划有助于解答他们的问题并缓解他们的担忧。

§

段落符号或分节符号

.'

。'

'The VIRTUGUIDE™ System is a pivotal advancement in AI-powered surgical precision for treating bunion deformities—a common, painful, and potentially debilitating condition affecting nearly one-third of Americans

“VIRTUGUIDE™ 系统是用于治疗拇囊炎畸形的 AI 驱动手术精确性的一项关键进步——拇囊炎是一种常见、痛苦且可能致残的疾病，影响着近三分之一的美国人。”

4

4

,' said Oray Boston, Worldwide President of Trauma, Extremities, Craniomaxillofacial, Animal Health and Sports Medicine, Orthopaedics, Johnson & Johnson MedTech. 'This milestone marks an important step forward, as VIRTUGUIDE™ becomes the latest addition to our growing portfolio of VELYS™ Enabling Tech solutions.

奥雷·波士顿（Oray Boston），强生医疗科技骨科创伤、四肢、颅颌面、动物健康与运动医学全球总裁表示：“这一里程碑标志着我们迈出了重要的一步，VIRTUGUIDE™成为了我们不断扩展的VELYS™赋能技术解决方案组合中的最新成员。”

By automating surgical planning and tailoring instrumentation to each patient, the system helps reduce complexity in the operating room and helps surgeons to achieve the intended correction.

通过自动化的手术规划和为每位患者定制的仪器，该系统有助于降低手术室的复杂性，并帮助外科医生实现预期的矫正。

2

2

,7

，7

**.'

**.'

This launch follows the 510(k) clearance from the U.S. Food & Drug Administration (FDA) for the Pre-operative Planning Software, granted earlier this year.

此次发布是在今年早些时候获得美国食品药品监督管理局 (FDA) 的 510(k) 许可之后进行的，许可内容为术前规划软件。

‖

‖

The system is now available in the U.S. For more information, visit

该系统现在在美国可用。欲了解更多信息，请访问

https://www.jnjmedtech.com/en-US/product/virtuguide-system

https://www.jnjmedtech.com/zh-CN/product/virtuguide-system

.

。

Orthopaedic Solutions from Johnson & Johnson MedTech

强生医疗科技骨科解决方案

Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. In Orthopaedics, we are on a mission to keep people moving by leveraging our deep expertise in joint reconstruction, robotics and enabling tech, spine, sports, trauma, and extremities, to develop the next generation of medtech solutions.

在强生公司，我们正在应对世界上最复杂和普遍的健康挑战。在骨科领域，我们致力于通过运用我们在关节重建、机器人技术及赋能科技、脊柱、运动医学、创伤和四肢方面的深厚专业知识，开发下一代医疗技术解决方案，以保持人们的活力。

We offer one of the most comprehensive Orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. For more, visit our .

我们提供世界上最全面的骨科产品组合之一，帮助我们服务的数百万患者治愈并恢复运动。欲了解更多信息，请访问我们的网站。

website

网站

or follow us on

或者关注我们

LinkedIn

领英

.

。

About Johnson & Johnson

关于强生公司

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

在强生，我们相信健康就是一切。我们在医疗保健创新方面的实力使我们能够构建一个世界，在这个世界中，复杂疾病得以预防、治疗和治愈，治疗方法更加智能且侵入性更小，解决方案也更加个性化。凭借我们在创新药物和医疗技术方面的专业知识，我们有能力在当今整个医疗保健解决方案领域进行创新，提供明天的突破性成果，并对人类健康产生深远影响。

Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at .

了解我们医疗技术部门在全球范围内的规模，以及在心血管、骨科、外科和视力解决方案方面的深厚专业知识。

https://thenext.jnjmedtech.com

https://thenext.jnjmedtech.com

. Follow us at

关注我们

@JNJMedTech

@JNJMedTech

and on

并且继续

LinkedIn

领英

. DePuy Synthes Products, Inc. is a Johnson & Johnson company.

DePuy Synthes Products, Inc. 是强生公司旗下企业。

Cautions Concerning Forward-Looking Statements

关于前瞻性陈述的注意事项

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding the VIRTUGUIDE™ System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.

本新闻稿包含《1995年私人证券诉讼改革法案》中定义的关于VIRTUGUIDE™系统的“前瞻性声明”。读者请注意，不要过度依赖这些前瞻性声明。这些声明基于对未来事件的当前预期。如果基本假设被证明不准确，或已知或未知的风险或不确定性成为现实，实际结果可能与强生公司的预期和预测大相径庭。

Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment.

风险和不确定性包括但不限于：商业成功的不确定性；专利挑战；竞争，包括技术进步、竞争对手获得的新产品和专利；生产困难和延误；产品功效或安全问题导致的产品召回或监管行动；适用法律法规的变更，包括全球医疗改革；医疗卫生产品和服务购买者的行为和支出模式的变化；以及控制医疗成本的趋势。

A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

这些风险、不确定性和其他因素的进一步列表和描述可以在强生公司最近的年度报告 Form 10-K 中找到，特别是标题为“关于前瞻性陈述的警示声明”和“项目1A. 风险因素”的部分，以及强生公司随后的季度报告 Form 10-Q 和提交给证券交易委员会的其他文件中。

Copies of these filings are available online at .

这些文件的副本可在线获取。

www.sec.gov

www.sec.gov

,

，

www.jnj.com

www.jnj.com

or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

或应Johnson & Johnson的要求。Johnson & Johnson不承担因新信息或未来事件或发展而更新任何前瞻性声明的义务。

Important Information: Prior to use, refer to the instructions for use supplied with the device(s) or indications, contraindications, warnings and precautions.

重要信息：使用前，请参阅设备附带的使用说明或适应症、禁忌症、警告和注意事项。

© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ORT_FTAK_398543

© 强生公司及其关联公司2025年。保留所有权利。US_ORT_FTAK_398543

* Statements are based on responses from 10 surgeons, having completed a total of 150 Lapidus procedures using the VIRTUGUIDE™ System. The statements reflect surgeon experience, not clinical outcomes, and were included if at least 6 surgeons agreed.

* 陈述基于10位外科医生的反馈，他们使用VIRTUGUIDE™系统完成了共计150例Lapidus手术。这些陈述反映的是外科医生的经验，而非临床结果，并且至少需要6名外科医生达成一致才被纳入。

** VIRTUGUIDE™ System compared to Treace Medical Lapiplasty

** VIRTUGUIDE™ 系统与 Treace Medical Lapiplasty 对比

®

®

3-Plane System and Paragon28 Bun-Yo-Matic Lapidus Clamp System.

三平面系统和Paragon28 Bun-Yo-Matic Lapidus夹具系统。

±

±

Dr. Michael Campbell, M.D., FAAOS is a paid consultant for Johnson & Johnson MedTech.

迈克尔·坎贝尔博士，医学博士，FAAOS，是强生医疗科技的付费顾问。

§

§

These statements reflect the experience, approach and opinion of the surgeon.

这些声明反映了外科医生的经验、方法和观点。

‖ The VIRTUGUIDE™ Planning Software, powered by PeekMed

‖ VIRTUGUIDE™ 规划软件，由 PeekMed 提供支持

®

®

, is developed and owned by Peek Health, S.A. Refer to

，由Peek Health, S.A.开发并拥有。参见

help.peekmed.com

help.peekmed.com

for user manuals, FAQ's, or any support.

对于用户手册、常见问题或任何支持。

The third-party trademarks used herein are trademarks of their respective owners.

本文中使用的第三方商标是其各自所有者的商标。

1

1

Johnson & Johnson MedTech, VIRTUGUIDE™ System Early Surgeon Experience Report December 2024, Windchill Document# EM24-0028

强生医疗科技，VIRTUGUIDE™ 系统早期外科医生经验报告，2024年12月，Windchill 文件编号# EM24-0028

2

2

Johnson & Johnson and its affiliates VIRTUGUIDE™ System Feature Memo. 9th Dec 2024. Windchill # EM24-0027.

强生公司及其关联公司 VIRTUGUIDE™ 系统功能备忘录。2024年12月9日。Windchill 编号 EM24-0027。

3

3

American Orthopaedic Foot & Ankle Society. Lapidus Procedure.

美国骨科足踝外科协会。Lapidus手术。

FootCareMD

足部护理医学

. Accessed June 24, 2025.

。访问日期：2025年6月24日。

https://www.footcaremd.org/conditions-treatments/toes/lapidus-procedure

https://www.footcaremd.org/conditions-treatments/toes/lapidus-procedure

4

4

MedlinePlus. Bunion: Genetic and Environmental Causes. U.S. National Library of Medicine. Available at

MedlinePlus. 拇囊炎：遗传和环境原因。美国国家医学图书馆。可用资源于

https://medlineplus.gov/genetics/condition/bunion/

https://medlineplus.gov/genetics/condition/bunion/

. Accessed March 2025.

. 2025年3月访问。

5

5

Rupke T. The modified Lapidus procedure for the treatment of moderate to severe hallux valgus.

鲁普克 T. 改良Lapidus手术治疗中重度拇外翻。

Orthogate

正交门

. Published October 30, 2013. Accessed June 26, 2025.

发布于2013年10月30日，访问于2025年6月26日。

https://www.orthogate.org/articles/foot-and-ankle/81306-the-modified-lapidus-procedure-for-the-treatment-of-moderate-to-severe-hallux-valgus

https://www.orthogate.org/articles/foot-and-ankle/81306-改良Lapidus手术治疗中重度拇外翻

6

6

Foran IM, Lin J, Hamid KS, Lee S. Technical tip: kerfing for Lapidus arthrodesis: deformity correction with minimal bone resection.

Foran IM, Lin J, Hamid KS, Lee S. 技术提示：Lapidus关节融合术中的刻槽技术：通过最小的骨切除进行畸形矫正。

J Foot Ankle Surg

足踝外科杂志

. 2021;60(2):424-427. doi:10.1053/j.jfas.2020.10.004

. 2021;60(2):424-427. doi:10.1053/j.jfas.2020.10.004

7

7

Sobrón FB, Santos-Vaquinhas AD, Alonso B, et al. Technique tip: 3D printing surgical guide for pes cavus midfoot osteotomy.

索布龙 FB，桑托斯-瓦金哈斯 AD，阿隆索 B，等。技术提示：用于高弓足中足截骨术的3D打印手术导板。

J Foot and Ankle Surgery

足踝外科杂志

. 2022;28:371-377.

. 2022;28:371-377.

Media Contacts:

媒体联系人：

Erin Farley

艾琳·法利

efarley1@its.jnj.com

efarley1@its.jnj.com

Abhi Basu

阿比·巴苏

abasu26@its.jnj.com

abasu26@its.jnj.com

Investor Contact:

投资者联系：

investor-relations@its.jnj.com

投资者关系@its.jnj.com

View original content to download multimedia:

查看原始内容以下载多媒体：

https://www.prnewswire.com/news-releases/johnson--johnson-launches-virtuguide-ai-powered-patient-matched-lapidus-system-in-us-to-reduce-complexity-in-bunion-surgery-for-millions-302515344.html

https://www.prnewswire.com/news-releases/强生公司推出VirtuGuide-人工智能驱动的患者匹配Lapidus系统在美国上市-以减少数百万拇囊炎手术的复杂性-302515344.html

SOURCE Johnson & Johnson MedTech

来源：强生医疗科技